Immatics Announces Upcoming Oral Presentation at ESMO Congress 2024

Full abstracts will be available on the ESMO website on Monday, September 9, 2024, at 00:05 CEST. Date / Time: September 16, 2024 / 11:25 CEST Session: Investigational Immunotherapy Title: Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation Presenting author: Martin Wermke, MD (University Hospital Dresden, Germany) Room: Granada Auditorium - Hall 6 IMA401 is Immatics' most advanced TCER® molecule tha ...